The Only Industry-Focused Gene Editing Meeting
By spotlighting the emerging cutting-edge technologies, whilst also battling the key challenges limiting preclinical and clinical success, the 6th Genome Editing Therapeutics Summit sought to provide you and your team with the insights needed to maximize the potential for your therapies.
Attendees collaborated with senior experts working across discovery, R&D, delivery, preclinical and clinical development, to streamline their end-to-end development. They also heard the latest data, from novel technologies and innovative platforms through to the leading clinical programs, to support their building of robust strategies to break new therapeutic ground.
What You Missed
Leveraging learnings from leading assets to support your team in building unbreakable clinical strategies with Bluebird Bio
Identifying innovative technology platforms to improve editing accessibility and therapeutic safety with nChromaBio and Metagenomi
Evaluating the benefits of viral and non-viral approaches to mediate precise targeting with Mammoth Biosciences and nChromaBio
Enhancing translatability and boost scalability through biomarker discovery with Modalis Therapeutics and Apellis Pharmaceuticals
Discussing approaches to accelerate progression from discovery through to commercialization with Prime Medicine and Novartis
Attending Companies Include
I am excited to be a part of this summit, which brings together leading voices in this rapidly evolving field. This meeting provides a timely platform to explore how we can innovate and translate these tools into safe and effective therapies for patients
Anna Gough, Scientist, Tune Therapeutics, 2025 Speaker